Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the effects (good and bad) that the combination of
the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on
breast cancer. The United States (US) Food and Drug Administration has approved both
letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the
combination will work better than either drug alone.